Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CFO Sells 13,600 Shares of Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Thomas Trimarchi sold 13,600 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $74.72, for a total value of $1,016,192.00. Following the transaction, the chief financial officer directly owned 336,585 shares in the company, valued at $25,149,631.20. This represents a 3.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

BridgeBio Pharma Stock Down 2.5%

Shares of NASDAQ BBIO traded down $1.92 during trading on Wednesday, hitting $73.93. The company had a trading volume of 2,365,520 shares, compared to its average volume of 3,243,876. BridgeBio Pharma, Inc. has a fifty-two week low of $28.33 and a fifty-two week high of $84.94. The stock has a fifty day simple moving average of $75.70 and a two-hundred day simple moving average of $63.72. The firm has a market capitalization of $14.25 billion, a price-to-earnings ratio of -17.69 and a beta of 1.13.

Key Stories Impacting BridgeBio Pharma

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: HC Wainwright raised its price target to $100 and reiterated a Buy rating, signaling bullish analyst support that could underpin the stock. Benzinga
• Positive Sentiment: Several Wall Street firms maintain buy/overweight ratings and a median 6‑month target near $94, providing analyst-driven upside thesis for investors focused on BBIO’s pipeline and long-term growth. Analyst Coverage Summary
• Neutral Sentiment: BridgeBio will report Q4 and full‑year 2025 results after the close on Feb. 24 and host a 4:30 pm ET conference call — an event that can create short‑term volatility depending on revenue, cash burn and program updates. Earnings Release
• Neutral Sentiment: The company granted inducement RSUs to 34 new employees (76,701 aggregate shares) under Nasdaq rules; vesting schedules could modestly increase share-based compensation and future float. Inducement Grants
• Negative Sentiment: Multiple senior insiders sold stock on Feb. 17: Director Randal W. Scott (10,000 shares). These disclosed Form 4s reduce insider ownership and can spook investors when clustered. Scott Form 4
• Negative Sentiment: CFO Thomas Trimarchi sold 13,600 shares (≈$1.02M) and CAO Maricel Apuli sold 510 shares; clustered executive selling raises near‑term governance/ownership concerns for some investors. Trimarchi Form 4 Apuli Form 4
• Negative Sentiment: Data providers note a long history of insider sales (many officers have sold substantial blocks over recent months), which can weigh on sentiment even as analysts remain constructive. Insider/Analyst Summary

Analysts Set New Price Targets

A number of brokerages recently issued reports on BBIO. Morgan Stanley assumed coverage on shares of BridgeBio Pharma in a research note on Tuesday, January 6th. They issued an “overweight” rating and a $96.00 price target for the company. Oppenheimer boosted their price objective on shares of BridgeBio Pharma from $81.00 to $83.00 and gave the company an “outperform” rating in a research note on Friday, February 13th. HC Wainwright raised their price target on BridgeBio Pharma from $90.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday. Wells Fargo & Company lifted their price objective on BridgeBio Pharma from $88.00 to $98.00 and gave the stock an “overweight” rating in a report on Friday, February 13th. Finally, Leerink Partners increased their target price on BridgeBio Pharma from $75.00 to $86.00 and gave the stock an “outperform” rating in a research report on Monday, December 15th. Twenty-two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $82.05.

Institutional Trading of BridgeBio Pharma

A number of institutional investors have recently added to or reduced their stakes in the business. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of BridgeBio Pharma during the second quarter worth about $25,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of BridgeBio Pharma during the 3rd quarter worth about $31,000. Harvest Fund Management Co. Ltd acquired a new position in BridgeBio Pharma in the 3rd quarter valued at $34,000. Jones Financial Companies Lllp acquired a new position in shares of BridgeBio Pharma during the 1st quarter worth approximately $35,000. Finally, First Horizon Corp acquired a new stake in shares of BridgeBio Pharma during the 3rd quarter worth $36,000. 99.85% of the stock is currently owned by institutional investors and hedge funds.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.